GO
Loading...

Takeover Bids

More

  • Cramer: Can't lose if you're Ackman     Wednesday, 23 Apr 2014 | 9:17 AM ET

    The "Squawk on the Street" news team discuss the involvement of Bill Ackman in the deal between Valeant Pharmaceuticals and Allergan.

  • William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.

  • Ackman: Allergan clear fit for Valeant     Wednesday, 23 Apr 2014 | 7:41 AM ET

    William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.

  • J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.

  • Valeant CEO: Allergan has a great set of assets     Wednesday, 23 Apr 2014 | 7:33 AM ET

    J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.

  • Ackman: Valeant fit into Pershing investing mold     Wednesday, 23 Apr 2014 | 7:32 AM ET

    William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.

  • Einhorn's new course     Tuesday, 22 Apr 2014 | 2:31 PM ET

    Sandy Villere, Villere Funds, shares his thoughts on Greenlight Capital's new stake in Conn's.

  • Pharma deal frenzy     Tuesday, 22 Apr 2014 | 10:01 AM ET

    CNBC's Meg Tirrell digs into the friendly and hostile M&A action taking place in pharmaceuticals, including a deal between Novartis and GlaxoSmithKline, and Valeant Pharmaceuticals bid for Allergan.

  • Valeant's offer for Allergan     Tuesday, 22 Apr 2014 | 8:03 AM ET

    Valeant Pharmaceuticals offered $48.30 share cash, as well as 0.83 shares for Allergan. CNBC's Meg Tirrell provides insight.

  • Ackman & Valeant's bid for Allergan     Tuesday, 22 Apr 2014 | 7:04 AM ET

    In an SEC Filing, Valeant Pharmaceuticals said it expected to offer a mix of stock and about $15 billion in cash for botox maker Allergan. David Krempa, Morningstar equity analyst, and CNBC's Meg Tirrell, provide perspective.

  • Valeant, Ackman make $45.6B Allergan bid Tuesday, 22 Apr 2014 | 12:03 AM ET

    NEW YORK— Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion. Each Allergan share would be exchanged for $48.30 in cash and 0.83 shares of Valeant Pharmaceuticals International Inc. common stock.

  • *Rejects shareholder Vintage Capital's $2.3 bln offer. April 15- Aaron's Inc, a rent-to-own furniture and electronics retailer, rejected a $2.3 billion takeover offer from a major shareholder and instead bought a web-based retail credit financing firm for about $700 million to provide customers with easier payment terms.

  • April 15- Hedge fund Elliott Management reaffirmed its $3.36 billion offer for network gear maker Riverbed Technology Inc after being rebuffed twice, saying it remained "extremely interested" in acquiring the company. The stock had touched a high of $22.76 in February after Elliot raised its initial bid by $2 to $21 per share.

  • April 15- Hedge fund Elliott Management reaffirmed its $3.36 billion offer for network gear maker Riverbed Technology Inc, saying it remained "extremely interested" in acquiring the company. Riverbed rejected Elliott Management's raised bid in February, saying the offer undervalued the company.

  • April 15- Aaron's Inc, a rent-to-own furniture and electronics retailer, rejected a $2.3 billion takeover offer from a major shareholder and instead acquired a retail credit financing firm for about $700 million.

  • JGBs little changed, 5-yr auction draws solid bids Tuesday, 15 Apr 2014 | 1:12 AM ET

    TOKYO, April 15- Japanese government bond prices were little changed on Tuesday, erasing small earlier losses after an auction of five-year JGBs drew solid bids. The 10- year JGB futures ticked up 0.04 point to 145.09, coming back from the day's low of 144.99.

  • April 14- China- focused hospital operator Chindex International Inc received a buyout offer of $23 per share, higher than the $19.50 offered by Shanghai Fosun Pharmaceutical Group and private equity firm TPG in February. Chindex, which runs the United Family Healthcare hospitals in China, did not name the new bidder.

  • TORONTO/ VANCOUVER, April 10- Goldcorp Inc raised its hostile takeover offer for Osisko Mining Corp on Thursday, squeaking above a white knight bid by Yamana Gold Inc and heightening a bidding war that has helped inject life into a depressed gold mining sector.

  • *Battle for Deoleo turned political this week. MADRID, April 10- The board of Spain's Deoleo, the world's top olive oil bottler, agreed on Thursday to back a takeover bid from British private equity fund CVC Capital Partners.

  • TORONTO/ VANCOUVER, April 10- Goldcorp Inc raised its hostile takeover offer for Osisko Mining Corp on Thursday, squeaking above a white knight bid by Yamana Gold Inc and heightening a bidding war that has helped inject life into a depressed gold mining sector.

Most Popular Video

Wednesday, 23 Apr 2014 | 10:50 PM ET

Taro Kono, Member of the House of Representatives in Japan's Parliament, says the Liberal Democratic Party (LDP) stands behind Prime Minister Shinzo Abe in pushing for the TPP trade deal.

Wednesday, 23 Apr 2014 | 10:34 PM ET

Charles Li, Chief Executive of Hong Kong Exchanges and Clearing, says the launch of a new commodity trading platform for three metal contracts will facilitate long-term cross-border investments.

Wednesday, 23 Apr 2014 | 10:16 PM ET

David Garrity, Principal at GVA Research, says Apple's decision to raise its dividend and step up its stock buyback program signaled confidence in the tech giant's outlook.